Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

  • Technology appraisal guidance
  • TA341
  • Published: 

History

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban [ID726]: equality impact assessment - guidance review

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban [ID726]: final appraisal determination

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban: equality impact assessment - scoping

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban: response to consultee and commentator comments on the draft scope and provisional matrix (post-referral)

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban: final matrix

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban: final scope

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban: draft scope for consultation (pre-referral) - January 2014

Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban: provisional matrix (pre-referral) - January 2014